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GLOSSARY OF ABBREVIATIONS 
ADR   Adverse drug reaction 
ATC   Anatomical therapeutic chemical classification system 
BMD   Bone mineral density 
BRONJ  Bisphosphonate-related osteonecrosis of the jaw 
CDC   Centers for Disease Control and Prevention 
CI     Confidence interval 
DDD   Defined daily dose 
DEXA  Dual-energy X-ray absorptiometry 
EMA   European Medicines Agency 
ENDO  Endocrine Society 
FDA   Food and Drug Administration 
FRAX   Fracture risk assessment tool 
HCSO   Hungarian Central Statistical Office 
HR   Hazard ratio 
HUF   Hungarian forints 
ICD   International classification of diseases 
IOF   International Osteoporosis Foundation 
IU     International unit 
NHANES  National health and nutrition examination survey  
NHIF   National Health Insurance Fund 
NNH   Number needed to harm 
NOS   National Osteoporosis Society 
OP    Osteoporosis 
OR   Odds ratio 
OTC   Over the counter 
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PIM   Potentially inappropriate medication 
PP    Polypharmacy 
PPV   Positive predictive value 
SD    Standard deviation 
SPC   Summary of product characteristics 
TID   Thousand inhabitants per day 
USPTF   U.S. Preventive Services Task Force  
UVB   Ultraviolet radiation B 
WHO   World Health Organisation 
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Figure 1 Percentage distribution of the 60+ age group by country in 2015 and 2050 [5] 
1. INTRODUCTION 
Geriatric falls are the leading causes of hospital trauma admissions and injury-related 
deaths among older adults [1, 2]. Approximately one-third of community-dwelling elderly 
above the age of 65 fall at least once a year, resulting in bone fractures, worsened quality of 
life, loss of independence, fear of falling, disability and early death [3, 4].  
Population aging is a well-documented, growing problem in developed countries 
nowadays. The proportion of older adults is remarkably increasing; it is estimated that the 
number of people over 60 years will rise from 901 million in 2015 to 2.1 billion by the year 
2050 [5]. For example, in Hungary this age group will increase from 24.9% to 34.6% between 
the years 2015 and 2050, but in China the rate will double (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
Among the elderly, medication use is a crucial element among extrinsic risk factors for falls 
[6]. It is proven and well known that older people account for the highest proportion of 
medication costs, as the number of chronic diseases rapidly increases with age [6, 7].  
Even though comorbidities in older people often require taking numerous prescription drugs, 
taking 4 or more chronic medications (defined as polypharmacy) was found to be an 
independent risk factor for falls [8, 9]. Polypharmacy (PP) also increases the prevalence of 
drug-related problems, such as drug–drug interactions, adverse drug reactions, prescription 
errors and non-adherence [10, 11]. Though there is no consensus about the exact cut-off value 
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for polypharmacy, usually it is defined as the concomitant use of more than or equal to  
4-8 chronic medications [6, 12, 13]. Polypharmacy is quite common in geriatric patients: the 
prevalence in the U.S. is around 57%, while a large European study reported 39.4% above the 
age of 65 [14, 15]. To reduce the risk of falls and to minimize the prevalence of adverse drug 
reactions, potentially inappropriate medication (PIM) lists have been implemented, among 
which the ‘Beers criteria’ is the most widely used, outstarter list [16]. Initially its use was 
restricted for nursing home residents, then it was extended for any geriatric patients. The most 
recently updated (2015) list identifies not only the potentially inappropriate drugs, but also 
offers recommendation on alternative medications or therapies [17]. Following the Beers 
criteria, numerous countries have created their specific national PIM list, adding or 
withdrawing medications, adapted to the country’s therapeutic practice and pharmaceutical 
market. Using these medication lists is a substantial strategy to reduce the risk of adverse 
events and falls in older adults, however, the lists are hardly confirmed by real 
epidemiological data. According to the Centers for Disease Control and Prevention (CDC), 
approximately 5% of adults above 65 years live in nursing homes, but these residents account 
for about 20% of deaths from falls in this age group [1]. Although many falls remain 
unreported, patients often fall more than once a year. In a typical nursing home, the annual 
average number of falls is 2.6 per patient [1]. Therefore guidelines and policies on fall 
prevention need to be adverted on populations under the greatest risk, such as nursing home 
residents.  
Other than medication use, many studies have revealed a variety of factors or conditions 
that can increase the risk of falling in elderly patients, such as older age, comorbidities, 
vitamin D deficiency, vision disturbances, diabetes, depression and osteoporosis [6, 8, 18]. In 
the present thesis, osteoporosis and serum vitamin D level have been studied as risk factors 
for falls (and fractures).  
Osteoporosis (OP) is a metabolic bone disease, characterised by decreased bone mass, 
quality and strength, and increased susceptibility to fracture, even to minimal trauma (such as 
falls) (Figure 2) [19]. Therefore osteoporotic patients with brittle bones are under high risk of 
developing low-energy fractures - as a consequence of falls. Thus, prevention and treatment 
of osteoporosis is an important challenge, which cannot be accomplished without identifying 
the population at greatest risk. 
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Figure 2 This three-dimensional photographic study shows the progression of vertebral body 
from normal bone density to moderate osteoporosis and severe osteoporosis [20]. 
(Permission to use images granted by Professor Alan Boyde.)  
 
 
 
 
 
 
 
 
 
 
The incidence of OP increases with age, occurring mainly above the age of 50 years. 
In Germany, 6.3% of the population (around five million patients) were diagnosed with 
osteoporosis in 2009, reported by a recently published epidemiologic study [21].  
Osteoporosis is mostly defined as the disease of women, because the prevalence and fracture 
rates are much higher among females. However, the disease affects a significant portion of 
men, as well. From the 10 million residents of Hungary, it is estimated that in the population 
over 50 years of age 547,107 people suffered from osteoporosis, of which 94,949 were males 
and 452,158 were females in 2010 [22, 23]. Similar prevalence rates were found in the 
European Union, while the rate was higher in the U.S.A. [18, 22, 23]. Amongst fall-related 
low-energy bone fractures, hip fractures are the most significant consequences of 
osteoporosis: they put a huge financial burden on the health care system and on the patients as 
well, besides extreme pain and high morbidity and mortality rates.  
These types of fractures require urgent surgical intervention, hospitalisation and 
prolonged rehabilitation, yet nearly 25% of people with hip fracture will die within one year. 
Although falls and fractures are more common among older women than men, in the case of 
hip fracture the mortality rate is almost double in males than in females: 26.8-32.5% versus 
17.0-21.9% [18, 22-32]. There are approximately 100,000 osteoporotic bone fractures each 
year in Hungary, and the treatment costs are estimated to be more than 20 billion HUF 
(Hungarian Forints, about 64.5 million EUR) for the National Health Insurance Fund (NHIF) 
in 2011. At the same time, the expenses of pharmacological prevention and treatment take 
only 8 billion HUF (26 million EUR), moreover, 50% of osteoporotic fractures would be 
preventable with appropriate pharmacological treatment and with screening the population at 
risk [33]. 
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Besides osteoporosis, many studies have proven that low vitamin D level increases the 
risk of bone fractures. Adequate vitamin D level is essential to prevent bone loss and 
structural damage of the bone matrix, which also prevents fractures. Though there are 
insufficient data to confirm a causal relationship between vitamin D deficiency and the 
immune, cardiovascular, and metabolic systems, many epidemiological studies proved that 
low levels of vitamin D are important risk factors in several diseases, such as diabetes, 
cardiovascular diseases, hypertension, cancer or in autoimmune diseases [34-38]. Low 
vitamin D levels are also associated with decreased muscle strength and coordination, which 
can lead to falls [39, 40].  
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2. AIMS 
Our objective was to identify the main risk factors of geriatric falls on different 
population levels.  
a) A gender- and age-specific analysis was performed regarding the utilisation of anti-
osteoporotic drugs on national level in Hungary, covering a 5-year period  
(between 2007 and 2011). Further goals were to analyse the differences of treatment 
characteristics and hip-fracture trends between males and females, and to compare 
our results with those in other European countries.  
b) Secondly, our aim was to evaluate the medication use of nursing home residents by 
using the Hungarian PIM list - created and developed by our research group-,  
as well as to investigate the possible predictors of geriatric falls annualised over a  
5-year-long period (between 2011 and 2015), under the frame of a cohort study.  
c) Finally, in a pilot study, we compared vitamin D levels of elderly, hospitalised hip 
fractured patients with hospitalised non-fractured patients. Additionally,  
the prevalence of falls was detected and the differences between the groups were 
analysed.  
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3. MATERIALS AND METHODS 
3.1. Gender- and age-specific utilisation study of anti-osteoporotic drugs 
3.1.1. Data source 
The source of our crude data was the Hungarian National Health Insurance Fund 
(NHIF), which is the sole, mandatory, national health insurance fund, covering 100% of the 
Hungarian population (roughly 10 million people). All prescription claims are recorded by the 
providers; the NHIF database contains data on age, gender, residence, date of claim, 
medication, and diagnosis by ICD codes (International Classification of Diseases, 2010) [41]. 
Microsoft Access and Microsoft Excel programs were used for data management and 
analysis. For our study the NHIF provided anonymous, aggregated crude data; therefore this 
study did not require ethical approval. 
Our data for the European comparison came from the Estonian State Agency of 
Medicines, from the Baltic Statistics on Medicines, the Finnish Medicines Agency Fimea and 
Social Insurance Institution, and from the Norwegian Prescription Database [42-47].   
All results refer to the total population of each country.  
3.1.2. Database screening for anti-osteoporotic medications 
A retrospective analysis was performed regarding anti-osteoporotic medication use in 
Hungary, for the period between 2007 and 2011. The following details on medication use 
were available in the crude data: calendar year (2007–2011), gender, age group  
(in 5-year-long clusters), ATC code (Anatomical Therapeutic Chemical Classification), active 
pharmaceutical ingredient, product name, strength, ICD code (first 3 digits), number of 
packaging units, number of patients, and total number of DDDs (Defined Daily Dose). The 
primary screening method was based on the ATC codes (2013 version) of drugs [48].  
ATC is a pharmaceutical, five-level, seven digit coding system. Active substances are divided 
into different groups according to the organ or system on which they act and to their 
therapeutic and chemical characteristics [48]. The ATC/DDD system was set up by the  
World Health Organisation (WHO), in order to serve as a tool for drug utilisation research, 
and to improve quality of drug use [49].  
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The screened drugs that are available for the treatment of osteoporosis in Hungary were 
the followings: vitamin D and analogues (ATC: A11CC02-05), calcium compounds 
(A12AA03-04, and A12AA13), bisphosphonates (M05BA02-08), bisphosphonate 
combinations (M05BB03-05), strontium ranelate (M05BX03), and denosumab (M05BX04). 
The DDD is the average maintenance daily dose of the medication used for its main 
therapeutic indication in adults [49]. The medication use of large populations is often 
expressed as the number of DDDs per 1000 inhabitants per day, which technical unit enables 
to compare the drug use of populations of different sizes [50]. To obtain standardised, 
DDD/1000 inhabitants/day (DDD/TID) unit, we calculated with the formula below:   
DDD/TID = DDD / 365 / population size x 1000. 
Drug utilisation data expressed in this way may provide a rough estimate of the proportion of 
the population treated daily with certain drugs. An estimated drug consumption of  
10 DDD/1000 inhabitants/day corresponds to a daily use of the investigated drug by 1% of 
the population within a defined area [46].   
For each year, the gender and age-standardised data on population size were gained 
from the Hungarian Central Statistical Office (HCSO) [51]. The youngest population 
receiving anti-osteoporotic treatment was the 40–44-year-old group. In 2007 the total 
Hungarian population was 10,055,783 inhabitants, out of which there were 4,928,988 people 
above the age of 40 years (2,158,031 males and 2,770,967 females), while in 2011 the total 
population was 9,971,727 inhabitants, out of which 5,010,276 people were above the age of 
40 years (2,201,817 males and 2,808,459 females) [51]. The secondary screening method was 
based on the indications of drugs, coded by ICD (included ICDs: E55-58, M80, M81).  
 
3.1.3. Further technical assumptions 
a) In the case of bisphosphonate combinations (alendronic acid + vitamin D, 
M05BB03, alendronic acid + vitamin D + calcium, M05BB05, risedronic acid + 
vitamin D + calcium, M05BB04) different vitamin D and calcium doses were found 
from those in the vitamin D and calcium monotherapy medications. Therefore, 
direct comparison on each vitamin D and calcium-containing medications was not 
possible, since DDD/TID values were also different in the combinations.  
These categories are presented separately. 
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b) To avoid any bias, drugs for the treatment of malignancies (ICD “C” group and 
M82, M85) were excluded from the final analysis. The rates of excluded drugs 
(expressed in DDD%) in the indication of cancer therapy were the followings: 
vitamin D and analogues 1.38%, calcium compounds 2.64%, bisphosphonates 
8.34%, bisphosphonate combinations 0.12%, denosumab and strontium ranelate less 
than 0.1%, all of which was roughly 3% of treated patients.  
3.1.4. Incidence of hip fractures 
Age- and gender-specific incidence of hip fractures was studied in 2007 and 2011 
in Hungary. Our crude data came from the “Tables of basic data on Hungarian health 
care” [52]. Hip fractures were identified according to ICD codes (S72.0, S72.1, and 
S72.2) (Figure 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fracture of neck of femur Pertrochanteric 
fracture 
Subtrochanteric 
fracture 
ICD:S72.0 ICD: S72.1 ICD: S72.2 
Figure 3 Anatomy of pelvis and hip and different types of hip fractures [53] 
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3.2. Medication use and fall prevalence among nursing home residents 
A retrospective analysis was performed regarding the medication use and fall 
prevalence in nursing home residents, all recruited from the same institution, between  
August 2011 and August 2015 in Szeged, Hungary.  
3.2.1. Patients and setting 
Every patient who was the resident of the investigated nursing home for at least  
12 months was included in the study. Patient data were recorded and analysed for the first  
12 months of residency, starting from the date of admission. Relevant medication lists and 
demographic information were collected from the patient medical documentation of the 
facility. Detailed data on falls were available from hospital discharge documents since, after 
noticed falls, all residents were admitted to hospital for further investigation according to the 
nursing home protocol. The nursing home provides residential accommodation, meals and  
24-hour personal care (residential nursing) for those who find it difficult to cope without 
assistance. The facility is fully accessible and barrier-free. Daily medical supervision is also 
ensured (neurologist and gerontologist). Due to the local policy, deceased patients were 
excluded from this study, since we had no data access to those patients’ medical information. 
The present study was approved by the Regional Human Biomedical Research Ethics 
Committee of the University of Szeged. 
3.2.2. Data analysis and statistical methods 
Microsoft Excel, IBM SPSS Statistics (version 23) and R (3.2.2) programs were used 
for data management and analysis. A Chi-squared test was applied to compare the categorical 
variables (e.g. gender) between the investigated groups, and Fisher’s test in case of 
polypharmacy. Student’s t-test was performed to compare the continuous variables (e.g. age, 
number of medications) between groups. 
Positive predictive value (PPV) 
We examined the prevalence and PPV with 95% confidence intervals (CI 95%),  
to estimate the possible impact of each medication (active substance) on risk of falls by the 
widely used, basic architecture (2 by 2 contingency table) of cohort studies [54]. PPV is the 
proportion of patients taking a particular (investigated) drug and who had fall(s). In other 
words it shows the probability of an outcome (fall) if the patient has the tested condition 
(takes the particular drug). These proportions only have limited validity in clinical practice, 
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however. The predictive values of a clinical test depend critically on the prevalence of the 
condition (falls) in the patients being tested within a particular environment [55].  
Number needed to harm (NNH) 
NNH was calculated for those active agents which had high PPV, and where the lower 
CI 95% value exceeded the annual fall prevalence rate. The NNH index expresses how many 
patients need to be exposed to a certain risk-factor (drug) to cause harmful effect (fall) in one 
patient over a specific time period (1 year) [56, 57]. Nevertheless, NNH values calculated in 
our study cannot be extended for the entire population of elderly people; they are valid only 
for those nursing home residents involved in this analysis. 
Binary logistic regression analysis  
Binary logistic regression analysis was carried out to determine the association of falls 
with other variables found signiﬁcant in univariate analysis. Logistic regression was 
characterised by the accuracy of test [56, 57]. 
Potentially inappropriate medications 
To identify the potentially inappropriate medications, four commonly used PIM lists 
have been adopted to the Hungarian drug market and to our data on medication use, i.e. the 
updated Beers criteria (2015), the French LaRoche list (2007), the German Priscus list (2010) 
and the Austrian Mann list (2012) [17, 58-60]. The adopted list consists of 94 drugs or active 
ingredients (PIMs), out of which 54 drugs (PIM fall risk) were considered high-risk drugs in 
terms of falls (based on the rationale of the original lists) [61]. The prevalence of exposure to 
these medicines was illustrated by Venn diagram [62]. The complete Hungarian PIM list can 
be found as a supplement of this thesis. 
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Table 1 Laboratory references of 25(OH)D3 vitamin (*based on national guidelines, this rate 
may vary in different countries) [63] 
3.3. Vitamin D levels of elderly hospitalised patients 
A prospective pilot study was done to compare vitamin D levels of hospitalised hip 
fractured patients with hospitalised non-fractured patients in Szeged, Hungary. The fractured 
group was recruited from the Traumatology Department and the control group was recruited 
from the Department of Internal Medicine and Geriatrics. The recruitment period was from 
2011 June to 2011 September. Control group was matched according to age and gender. 
Microsoft Excel and R (3.2.2) programs were used for data management and analysis. 
Student’s t-test was performed to compare the continuous variables (e.g. age, vitamin D level) 
between groups.  
An international consent uses 25(OH)D3 (cholecalciferol) as a reference to assess the 
general level of vitamin D in the body (Table 1). The normal blood level of vitamin D is 
between 30 and 40 ng/ml, and this range is also considered as laboratory reference range [63]. 
Cholecalciferol levels were measured with ELISA kit and were expressed in ng/ml. All hip 
fractures derived from falls; therefore fall prevalence rate was considered 100% in the 
fractured group. Subjects were asked about previous falls during a personal interview. The 
study was approved by the Regional Human Biomedical Research Ethics Committee of the 
University of Szeged. 
 
 
 
 
 
 
 
  
Laboratory references of 25(OH)D3 vitamin* 
above 30 ng/ml (above 75 nmol/L) Sufficiency (adequately supplied) 
< 30 ng/ml ( < 75 nmol/L) Insufficiency (deficient) 
< 20 ng/ml (< 50 nmol/L) Deficiency (seriously deficient) 
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Figure 4 Utilisation of anti-osteoporotic medications in Hungary 2007-2011 
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4. RESULTS 
4.1. Gender- and age-specific utilisation study of anti-osteoporotic drugs 
4.1.1. Gender- and population-based results 
As expected, medication use by females was substantially higher in the case of every 
medication than by males (Figure 4). During the examined 5-year period, the utilisation of 
vitamin D and analogues showed constant increase from 7.91 DDD/TID to 13.73 DDD/TID 
(Table 2). A similar tendency was revealed in female and male patients. However, there was 
an approximately ten-fold difference between genders, male patients were remarkably 
undertreated. Vitamin D can also be found in combination with bisphosphonates, therefore the 
overall consumption was higher. The utilisation of calcium compounds increased from  
1.43 DDD/TID in 2007 to 4.49 DDD/TID in 2011, which is a more than three-fold growth. 
This tendency mainly arose from the treatment of female patients; males were significantly 
undertreated (F:M ratio was 10.8 in 2011). As calcium occurs in combination with alendronic 
and risedronic acid, the total rate would be higher than above.  
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Table 2 Gender-standardised utilisation of anti-osteoporotic drugs between 2007 and 2011 in Hungary  
(Bis. = Bisphosphonate; F=female; M=male) 
Utilisation Drug 
Vitamin D 
& 
analogues 
Calcium Bis. total 
Bis. 
mono-
therapy 
Bis. 
combi-
nations 
Alendronic 
acid 
Ibandronic 
acid 
Risedronic 
acid 
Zoledronic 
acid 
Alendronic 
acid + 
Vitamin D 
Risedronic 
acid + 
Vitamin D 
+ Calcium 
Alendronic 
acid + 
Vitamin D 
+ Calcium 
Strontium 
ranelate 
Denosu-
mab 
DDD/TID  
ATC/ 
Years 
A11CC A12AA 
M05BA + 
M05BB 
M05BA M05BB M05BA04 M05BA06 M05BA07 M05BA08 M05BB03 M05BB04 M05BB05 M05BX03 M05BX04 
Total 2007 7.91 1.43 6.66 5.07 1.60 3.91 0.68 0.48 — 0.81 0.69 0.10 0.16 — 
  2008 8.09 2.03 7.04 4.24 2.80 3.30 0.79 0.14 <0.01 1.42 1.27 0.11 0.32 — 
  2009 9.44 2.87 7.27 3.88 3.39 2.75 0.99 0.14 <0.01 2.02 1.23 0.14 0.54 — 
  2010 11.05 3.66 6.85 3.58 3.28 2.25 1.12 0.21 <0.01 2.08 1.05 0.15 0.64 — 
  2011 13.73 4.49 6.22 3.42 2.81 1.94 1.11 0.37 <0.01 1.89 0.77 0.14 0.70 0.04 
                                
Female 2007 13.91 2.45 12.10 9.13 2.97 6.94 1.29 0.91 — 1.48 1.31 0.18 0.31 — 
  2008 14.23 3.52 12.78 7.62 5.16 5.84 1.51 0.27 <0.01 2.55 2.41 0.20 0.61 — 
  2009 16.62 5.04 13.18 6.98 6.20 4.83 1.88 0.26 <0.01 3.62 2.33 0.25 1.03 — 
  2010 19.48 6.43 12.49 6.49 6.00 3.96 2.13 0.39 <0.01 3.77 1.97 0.26 1.21 — 
  2011 24.13 7.89 11.39 6.26 5.14 3.46 2.12 0.67 <0.01 3.43 1.45 0.26 1.34 0.08 
                                
Male 2007 1.28 0.30 0.65 0.57 0.08 0.56 <0.01 <0.01 — 0.07 0.01 <0.01 <0.01 — 
  2008 1.30 0.38 0.69 0.50 0.19 0.50 <0.01 <0.01 — 0.18 0.01 <0.01 <0.01 — 
  2009 1.49 0.48 0.73 0.45 0.28 0.44 <0.01 0.01 — 0.24 0.02 0.02 <0.01 — 
  2010 1.73 0.61 0.63 0.37 0.26 0.35 — 0.02 <0.01 0.20 0.03 0.02 <0.01 — 
  2011 2.25 0.73 0.51 0.28 0.23 0.26 — 0.03 <0.01 0.19 0.02 0.02 <0.01 — 
                                
F:M ratio 2007 10.90 8.10 18.60 16.00 37.60 12.30 294.50 236.70 — 22.00 134.50 93.40 741.70 — 
  2008 11.00 9.20 18.40 15.20 26.50 11.70 1105.60 380.40 — 14.20 198.10 59.10 239.90 — 
  2009 11.10 10.50 18.10 15.50 22.30 10.90 1789.20 37.60 — 14.90 130.90 15.30 297.90 — 
  2010 11.30 10.60 19.90 17.70 23.00 11.30 — 24.50 55.20 18.40 57.20 12.30 304.30 — 
  2011 10.70 10.80 22.20 22.10 22.40 13.50 — 24.30 47.10 18.10 68.00 14.00 372.30 — 
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The total bisphosphonate use was 6.66 DDD/TID in 2007, it slowly increased in  
2008 and 2009, but for 2011 it dropped to 6.22 DDD/TID. Male patients were treated 
approximately 20 times less than women (F:M ratio was 22.2 in 2011).  
In 2007, monotherapy took roughly 75% of the total trade compared to 55% in 2011, 
since the use of bisphosphonate combinations gradually increased, and nearly reached the rate 
of monotherapy in females and in males as well (Figure 5). The most widely used agent was 
alendronic acid; however, during the 5-year-long period, the trade of alendronic acid in 
monotherapy halved (3.91 vs 1.94 DDD/TID), while the combination with vitamin D more 
than doubled (0.81 vs 1.89 DDD/TID). The trade of vitamin D and calcium combination with 
alendronic acid was 0.15 DDD/TID in 2011. Alendronic acid took almost two-third of the 
total bisphosphonate use in all investigated years. The use of risedronic acid was more or less 
constant. The rate of combination with vitamin D and calcium was double compared to 
monotherapy (0.37 vs 0.77 DDD/TID in 2011). It accounted for roughly one-fifth of all 
bisphosphonate trade in all years. Ibandronic acid took around 16% (1.11 DDD/TID in 2011) 
of the total bisphosphonate consumption, and it was prescribed only for women; in 2010 and 
in 2011 there was no use of it in the male population. Zoledronic acid use has remained 
marginal since 2007 on the Hungarian market with less than 0.01 DDD/TID.  
Strontium ranelate is mainly prescribed for women after the bisphosphonate therapy 
failed or could not be tolerated. The trade showed a constant increase since 2007  
(0.16 DDD/TID), for 2011 it reached 0.70 DDD/TID.  
Denosumab, a monoclonal antibody, was introduced to the Hungarian market in 2011 
and took 0.04 DDD/TID in that year.  
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Figure 5 Utilisation rate of bisphosphonates in Hungary 2007-2011 
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4.1.2. Gender- and age-standardised results 
The utilisation of bisphosphonates was the highest in the 75–79-year-old population in 
both genders, but with very different values: 49.27 DDD/1000females/day and 3.40 
DDD/1000males/day in 2011 (Table 3). The highest decrease in bisphosphonate utilisation 
was detected in the 40-54 age groups in both genders during the study period. The largest 
differences between genders could be seen in 2011 in all age groups. Strontium ranelate was 
prescribed to male patients only above the age of 60, but less than 0.05 DDD/1000males/day. 
In women, a remarkable rise can be seen in all age groups from 2007 to 2011. The trade of 
denosumab in females peaked in the 70–74-year-old population (0.37 DDD/1000females/day) 
in 2011. There was no denosumab use among male patients.  
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Table 3 Gender- and age-standardised results 
    
40-44 
years 
45-49 
years 
50-54 
years 
55-59 
years 
60-64 
years 
65-69 
years 
70-74 
years 
75-79 
years 
80-84 
years 
85 and 
over 
Females  
          
  
(DDD/1000females/day) 
Bisphosphonates 2007 0.10 1.40 8.18 18.82 30.77 43.36 49.93 48.26 36.18 15.33 
M05BA, M05BB 2008 0.05 1.22 8.05 18.72 31.37 44.92 52.58 53.38 39.94 17.02 
  2009 0.06 1.07 8.31 18.92 31.36 44.89 53.15 54.92 43.25 19.39 
  2010 0.05 0.72 7.17 17.79 28.54 41.14 49.72 53.24 42.93 19.44 
  2011 0.04 0.53 5.56 15.78 25.67 36.58 44.79 49.27 41.04 18.62 
  
% change 
2007-2011 
-59.6% -62.0% -32.1% -16.1% -16.6% -15.6% -10.3% 2.1% 13.4% 21.4% 
  
 
         
  
Strontium ranelate  2007 — 0.01 0.12 0.40 0.66 1.06 1.42 1.44 1.22 0.45 
M05BX03 2008 — 0.05 0.32 0.81 1.36 2.09 2.53 2.68 2.22 0.98 
  2009 — 0.07 0.54 1.39 2.32 3.58 4.20 4.32 3.65 1.76 
  2010 — 0.05 0.55 1.55 2.74 4.09 4.92 5.19 4.48 2.04 
  2011 — 0.04 0.52 1.64 2.95 4.31 5.33 5.85 5.20 2.72 
  
% change 
2007-2011 
— 523.6% 333.1% 307.8% 346.3% 306.8% 274.9% 306.5% 327.1% 505.1% 
  
 
         
  
Denosumab 
M05BX04 
2011 — — 0.08 0.12 0.23 0.24 0.37 0.30 0.12 — 
Males 
 
         
  
(DDD/1000males/day) 
Bisphosphonates  2007 0.01 0.09 0.67 1.25 1.96 2.87 3.56 4.20 3.20 1.50 
M05BA, M05BB 2008 — 0.12 0.67 1.29 2.03 3.10 3.75 4.51 3.73 1.53 
  2009 0.01 0.05 0.56 1.33 2.26 3.27 4.01 4.79 3.61 1.63 
  2010 — 0.06 0.36 1.12 1.78 2.95 3.45 3.88 3.58 1.71 
  2011 — 0.01 0.16 0.80 1.44 2.30 2.96 3.40 3.43 1.56 
  
% change 
2007-2011 
— -85.5% -76.7% -35.7% -26.6% -19.7% -16.8% -19.0% 7.1% 4.2% 
  
 
         
  
Strontium ranelate  2007 — — — — — — 0.01 — — — 
M05BX03 2008 — — — — — 0.02 0.03 0.01 0.03 — 
  2009 — — — — — 0.02 0.04 0.04 0.02 — 
  2010 — — — — 0.01 0.03 0.02 0.05 — 0.04 
  2011 — — — — 0.01 0.02 0.03 0.01 0.05 0.03 
  
% change 
first trade 
year - 2011 
— — — — — 5.5% 122.4% -29.1% 68.2% -21.6% 
  
 
         
  
Denosumab 
M05BX04 
2007-2011 — — — — — — — — — — 
 
 
 
 
 20 
 
4.1.3. Comparison with European countries  
Comparable DDD/TID values of anti-osteoporotic medication use were available from 
2008 in Estonia, from 2009 in Finland, from 2010 in Latvia and Lithuania, and from 2007 in 
Norway; however, published age- and gender-matched data have not been found for the same 
time period [42-47]. The comparison is presented in Table 4.  
Results on total bisphosphonate use differ in all investigated countries. The declining 
tendency and the utilisation rate were similar in Finland, in Norway, and in Hungary.  
In contrast, Estonian, Latvian and Lithuanian bisphosphonate use was about 2-3 times lower, 
but a slowly increasing tendency or constant rate (Lithuania) was present in all three Baltic 
countries. In Finland and in Hungary, alendronic acid monotherapy took the majority of the 
bisphosphonate trade, similarly to Norway, while in the Baltic countries the use of 
bisphosphonate agents was more various. Regarding bisphosphonate combinations, the use of 
alendronic acid and vitamin D combination was more or less constant in Latvia, Lithuania and 
in Hungary. In Finland, a certain decline was seen between 2009 and 2011, while the Estonian 
data on alendronic acid combination markedly increased, from 0.93 DDD/TID in 2008 to  
2.52 DDD/TID in 2011. No use of bisphosphonate combinations was noticed in Norway. 
Strontium ranelate consumption was the highest in Hungary in 2010 and in 2011, similarly 
high in Lithuania, with an approximately 5-10-fold difference between Estonia, but the 
tendency of use was increasing in all countries, except in Norway (strontium ranelate is not 
available). Denosumab utilisation was the highest in Finland in 2011 (0.37 DDD/TID).  
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Table 4 Gender- and age-standardised utilisation of specific anti-osteoporotic drugs between 2007 and 2011 in different countries 
DDD/TID Drug Bis. total 
Bis. mono-
therapy 
Bis. 
combi-
nations 
Alendronic 
acid 
Ibandronic 
acid 
Risedronic 
acid 
Zoledronic 
acid 
Alendronic 
acid + 
Vitamin D 
Risedronic 
acid + 
Vitamin D 
+ Calcium 
Alendronic 
acid + 
Vitamin D 
+ Calcium 
Strontium 
ranelate 
Denosu-
mab 
Country 
ATC/    
Years 
M05BA+ 
M05BB 
M05BA M05BB M05BA04 M05BA06 M05BA07 M05BA08 M05BB03 M05BB04 M05BB05 M05BX03 M05BX04 
Estonia 2008 3.34 2.41 0.93 1.17 0.79 0.44 — 0.9 — — 0.04 — 
 
2009 3.86 2.09 1.77 0.78 0.86 0.44 — 1.77 — — 0.04 — 
 
2010 4.52 2.10 2.42 0.65 0.93 0.52 — 2.42 — — 0.06 — 
 
2011 4.38 1.86 2.52 0.56 0.80 0.49 — 2.52 — — 0.09 0.01 
 
                          
Latvia 2010 3.74 2.55 1.19 <0.01 0.96 1.59 — 1.19 — — 0.42 <0.01 
 
2011 4.75 2.93 1.82 0.01 0.92 2.00 — 1.82 — — 0.47 0.02 
 
                          
Lithuania 2010 2.75 1.81 0.94 0.40 0.73 0.68 — 0.48 0.46 — 0.64 <0.01 
 
2011 2.66 1.71 0.95 0.37 0.73 0.61 — 0.45 0.50 — 0.53 0.07 
 
                          
Finland 2009 10.80 8.34 2.46 3.84 1.95 2.54 0.01 2.46 — — 0.07 — 
 
2010 8.89 7.02 1.87 3.08 1.83 2.10 0.01 1.87 — — 0.14 0.02 
 
2011 7.97 6.52 1.45 2.97 1.73 1.81 0.01 1.45 — — 0.32 0.37 
 
                          
Norway 2007 9.32 9.32 — 8.86 0.19 0.27 <0.01 — — — — — 
 
2008 9.32 9.32 — 8.94 0.16 0.22 <0.01 — — — — — 
 
2009 9.05 9.05 — 8.71 0.15 0.19 <0.01 — — — — — 
 
2010 9.00 9.00 — 8.71 0.12 0.17 <0.01 — — — — <0.01 
 
2011 8.81 8.81 — 8.56 0.10 0.15 <0.01 — — — — 0.07 
 
                          
Hungary 2007 6.66 5.07 1.60 3.91 0.68 0.48 — 0.91 0.69 0.10 0.16 — 
 
2008 7.04 4.24 2.80 3.30 0.79 0.14 <0.01 1.42 1.27 0.11 0.32 — 
 
2009 7.27 3.88 3.39 2.75 0.99 0.14 <0.01 2.02 1.23 0.14 0.54 — 
  2010 6.85 3.58 3.28 2.25 1.12 0.21 <0.01 2.08 1.05 0.15 0.64 — 
  2011 6.22 3.42 2.81 1.94 1.11 0.37 <0.01 1.90 0.77 0.14 0.70 0.04 
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4.1.4. Incidence of hip fractures 
Investigating the Hungarian incidence of hip fractures in 2007 and 2011 would probably 
provide a better understanding of the importance of osteoporosis treatment. According to the 
“Tables of basic data on Hungarian health care”, the highest incidence of osteoporotic hip 
fractures was 3332.8 per 100,000 females aged 85 above, and 2151.2 per 100,000 males for 
the same age group in 2011 [52]. An exponentially growing tendency with age can be seen in 
the incidence of osteoporotic hip fractures in both investigated years (Figure 6). The incidence 
between 2007 and 2011 was more or less constant, showing slightly elevating tendency above 
the age of 75 years in both genders. However, a remarkable 8.7% increase in absolute number 
of hip fractures could be seen (17,432 hip fractures in 2007 and 19,093 in 2011), owing 
probably to the increasing number of elderly people in the Hungarian society.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Incidence of hip fractures in 2007 and 2011 in Hungary 
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4.2. Medication use and fall prevalence among nursing home residents 
4.2.1. Demography 
A total of 197 nursing home residents were included in the study, 150 (76.2%) women 
and 47 (23.8%) men (Table 5). Among the 55 fallers 44 were females and 11 were males, 
therefore the annual fall prevalence rate was 27.9%. Out of the 142 non-faller residents, 106 
were females and 36 were males. The gender was not found to be a predisposing factor for 
falls (prevalence in males: 23.4% versus 29.3% in females, p>0.05). Bone fractures occurred 
in 24 patients (5 males and 19 females, 43.6% of fallers).  
Regarding age, fallers were older (84.0 years ± 7.0 years) than non-fallers (80.1 years ± 
9.3 years, p<0.01). The age above or equal to 80 years was found to be a significant risk 
factor for falls (p<0.001). Among fallers, 47 residents (85.5%) were 80 years old or older, and 
all the 13 multiple fallers (more than 1 fall per year) were in this group.  
Table 5 Study population characteristics. *Chi-squared test was applied for categorical 
variables, Student’s t-test for continuous variables, and Fisher’s test in case of polypharmacy. 
(Polypharmacy: concomitant use of minimum 4 or more chronic medications; PIM: 
Potentially inappropriate medication use; PIM fall risk: PIMs carrying risk of falls) 
 
 
    Fallers Non-fallers 
p-value* 
Total 
(55; 27.9%) (142; 72.1%) (197; 100.0%) 
Gender females (% of all females) 44 (29.3%) 106 (70.7%) 
p=0.427 
150 (76.2%) 
males (% of all males) 11 (23.4%) 36 (76.6%) 47 (23.8%) 
Age (years) mean ± SD 84.0 ± 7.0 80.1 ± 9.3 p=0.002 81.2 ± 8.9 
min-max 61 - 99 52 - 104 - 52 - 104 
Age group 80 years or older  (% of group) 47 (35.9%) 84 (64.1%) 
p<0.001 
131 (66.5%) 
Age group less than 80 years (% of group) 8 (12.1%) 58 (87.9%) 66 (33.5%) 
Number of 
chronic 
medications 
mean ± SD 9.1 ± 3.8 8.0 ± 3.9 p=0.093 8.32 ± 3.88 
min-max 3 - 19 0 - 18 - 0 - 19 
males (mean ± SD) 12.4 ± 4.0 6.9 ± 4.2 p<0.001 8.2 ± 4.7 
females (mean ± SD) 8.3 ± 3.3 8.4 ± 3.7 p=0.810 8.4 ± 3.6 
Polypharmacy yes (% of group) 54 (98.2%) 122 (85.9%) 
p=0.010 
176 (89.3%) 
no (% of group) 1 (1.8%) 20 (14.1%) 21 (10.7%) 
PIM yes (% of group) 40 (72.7%) 112 (78.9%) 
p=0.357 
152 (77.2%) 
no (% of group) 15 (27.3%) 30 (21.1%) 45 (22.8%) 
PIM fall risk yes (% of group) 39 (70.9%) 107 (75.3%) 
p=0.523 
146 (74.1%) 
no (% of group) 16 (29.1%) 35 (24.6%) 51 (25.9%) 
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4.2.2. Medication patterns 
The number of chronic medications taken did not significantly differ between fallers 
and non-fallers (9.1 ± 3.8 vs. 8.0 ± 3.9, p>0.05) (Table 5), but did differ among male fallers 
and male non-fallers (12.4 ± 4.0 vs. 6.9 ± 4.2, p<0.001). Also, polypharmacy (taking 4 or 
more chronic medications) was a significant risk factor of falls (p=0.01). Polypharmacy 
occurred in 85.9% among non-faller patients, but in 98.2% among fallers (p=0.01). 
4.2.3. Potentially inappropriate medications 
Regarding the prevalence of PIM medication use, 77.2% of the residents took one or 
more PIM-list positive drug, and there was no significance in prevalence between fallers and 
non-fallers (72.7% vs. 78.9%, p>0.05). Those PIMs carrying risk of falls were taken by 
70.9% of fallers and 75.3% of non-fallers (p>0.05). PIM use was illustrated on the so called 
Venn diagram (Figure 7A and Figure 7B). To provide better understanding, we considered 
implementing the age dimension into this visualisation.  
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Figure 7A Venn diagram illustrates the 
populations (sets) that were subject to multiple 
drug use: residents taking potentially 
inappropriate medications (PIM) with fall risk; 
fallers; patients who were 80 years old or 
older, and those who were not part of any of 
these three sets. 
Figure 7B Venn diagram illustrates the 
populations (sets) that were subject to 
multiple drug use: those residents taking 4 or 
more chronic drugs (Polypharmacy); fallers; 
patients who were 80 years old or older, and 
those who were not part of any of these three 
sets. 
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Except for 2 non-medicated residents, 195 were taking 227 different drugs, out of which 
22 drugs were taken by at least 10% of the patients (minimum 20 individuals). For the most 
prevalent drugs, positive predictive values (with 95% confidence intervals) were calculated to 
estimate the impact of each medication on fall risk (Table 6). Considering the 27.9% annual 
fall prevalence rate in the nursing home, the lower confidence interval exceeded this margin 
in case of trimetazidine (PPV (95% CI) 0.48 (0.30-0.66), vinpocetine 0.44 (0.31-0.59) and 
pantoprazole 0.40 (0.30-0.52). Hence, those drugs seem to be significant risk factors for falls 
(Figure 8). 
Table 6 Positive predictive values (PPV) of drugs (with 95% CI: confidence intervals). 
Displayed drugs were taken by minimum 20 individuals (10% of all residents).   
Active substance No. of takers (%) No. of fallers PPV (95% CI) 
trimetazidine 23 (11.68%) 11 0.48 (0.30-0.66) 
isosorbide mononitrate 20 (10.15%) 9 0.45 (0.26-0.65) 
vinpocetine 36 (18.27%) 16 0.44 (0.31-0.59) 
tiapride 28 (14.21%) 12 0.43 (0.27-0.60) 
atorvastatin 29 (14.72%) 12 0.41 (0.27-0.58) 
pantoprazole 52 (26.4%) 21 0.40 (0.30-0.52) 
allopurinol 21 (10.66%) 8 0.38 (0.21-0.58) 
glyceryl trinitrate 36 (18.27%) 13 0.36 (0.24-0.51) 
famotidine 33 (16.75%) 11 0.33 (0.21-0.49) 
levothyroxine sodium 30 (15.23%) 10 0.33 (0.20-0.50) 
acetylsalicylic acid 74 (37.56%) 24 0.32 (0.25-0.41) 
alprazolam 63 (31.98%) 20 0.32 (0.23-0.42) 
bisoprolol 33 (16.75%) 10 0.30 (0.18-0.46) 
amlodipine 42 (21.32%) 12 0.29 (0.18-0.42) 
pentoxifylline 29 (14.72%) 8 0.28 (0.15-0.45) 
metoprolol 43 (21.83%) 10 0.23 (0.14-0.36) 
furosemide 65 (32.99%) 15 0.23 (0.16-0.33) 
potassium chloride 68 (34.52%) 15 0.22 (0.15-0.31) 
perindopril and amlodipine 28 (14.21%) 6 0.21 (0.10-0.39) 
acenocoumarol 20 (10.15%) 4 0.20 (0.08-0.42) 
piracetam 40 (20.3%) 7 0.18 (0.09-0.31) 
metformin 22 (11.17%) 3 0.14 (0.05-0.34) 
 
Giving an example for better understanding, the 0.40 PPV of pantoprazole shows the 
proportion of patients who used pantoprazole and who had fall(s). This means that taking the 
drug increases the fall prevalence rate by approximately 12% (compared to the annual 27.9% 
fall prevalence rate).  
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Figure 8 Positive predictive values (PPV) of drugs (with 95% confidence intervals, CI 95%, 
N= number of drug users). Dashed red line shows the annual fall prevalence rate (27.9%) in 
the nursing home. Displayed drugs were taken by minimum 10% of all residents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For the same drugs, the number needed to harm (NNH, 95% CI) was calculated (groups were 
the following: particular drug user or non-user, and the outcome/risk was falls). Accordingly, 
approximately 4-5 patients are needed to be exposed to trimetazidine and vinpocetine use to 
sustain a fall, while this number is about 6 in the case of pantoprazole exposure (Table 7).  
Table 7 Number needed to harm (NNH) values (with 95% CI: confidence intervals) of 
trimetazidine, vinpocetine and pantoprazole (N: number of takers). 
 
 
 
Drugs (number of drug users) NNH 95 % CI 
trimetazidine (N=23) 4.5 2.3 - 55.1 
vinpocetine (N=36) 5.0 2.7 - 32.6 
pantoprazole (N=52) 5.9 3.2 - 47.0 
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These numbers are clinically remarkable. We would like to emphasize that the NNH values 
calculated above cannot be extended for the entire population of old people; they are valid 
only for the involved nursing home residents.   
The variables of the binary logistic regression model were the following: age group 80 
years and above, persons taking pantoprazole, vinpocetine or trimetazidine. The binary 
logistic regression confirmed the significant impact of the 80+ age group, pantoprazole, and 
vinpocetine on fall risk, odd ratios were respectively 3.92, 2.59 and 2.32, with 73.6% 
accuracy detected (Table 8).  
Table 8 Results of binary logistic regression analysis (CI: confidence interval; OR: odds ratio). 
 
4.2.4. Prevention and treatment of  osteoporosis 
We analysed the prevalence of anti-osteoporotic drugs among the nursing home residents. Out 
of 197 subjects, 6 females have received oral bisphosphonate therapy, evenly distributed 
between the ages of 64 and 95 years. All the six females received calcium and vitamin D 
supplementation as well. Furthermore, 20 individuals took vitamin D (only 3 male patients), 
and 7 subjects received calcium monotherapy (only 1 male patient).  
 
 
  
Variables Coefficients (p-value) OR (95% CI) 
age group 80 years old or above 1.3660 (p=0.00175) 3.92 (1.67 - 9.22) 
pantoprazole 0.9498 (p=0.01049) 2.59 (1.25 - 5.35) 
vinpocetine 0.8411 (p=0.03760) 2.32 (1.05 - 5.12) 
trimetazidine 0.7181 (p=0.13296) 2.05 (0.80 - 5.23) 
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Figure 9A Proportion of vitamin D levels of fractured and control patients 
4.3. Vitamin D levels of elderly hospitalised patients 
4.3.1. Demography 
Twenty-two patients were in the fractured group (mean age 84.1 years, SD ± 6.8) and 
33 patients were in the control group (mean age 80.5 years, SD ± 6.6); the majority of patients 
were women in both groups (Table 9). Therefore the investigated groups did not differ 
significantly in demographic pattern, as stated in the Methods section.  
 
Table 9 Study population characteristics. (*Student’s t-test.) 
    
Patients with 
hip fracture 
Patients with no 
fracture (controls) p- value* 
Total 
  
 
22; 40% 33; 60% 
 
55; 100% 
Gender 
females  20; 91% 29; 88% 
¯  
49; 89% 
males  2; 9% 4; 12% 6; 11%  
Age (years) 
mean ± SD 84.1 ±  6.8 80.5 ± 6.6 
p>0.05 
82.0 ± 6.84  
min - max 71-92 71-98 71-98 
Vitamin D 
level (ng/ml) 
mean ± SD 33.8 ± 17.2 39.7 ± 21.3 
p>0.05 
37.4 ± 19.8 
min - max 12.8 - 74.4 17.0 - 107.1 12.8 - 107.1 
 
 
4.3.2. Vitamin D level 
Serum vitamin D level was normal (sufficient; >30 ng/ml) in 66.7% of the controls, and 
in 45.4% of fractured patients. Vitamin D insufficiency (20-30 ng/ml) was higher in the 
fractured group (27.3% vs. 21.2%), as well as the prevalence of deficiency (<20 ng/ml) 
(27.3% vs. 12.1%), though we couldn’t find any statistical significance between the groups 
(Figure 9A). 
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Figure 9B Distribution of fractured (blue) and control patients (yellow) by vitamin D levels 
Figure 10 Prevalence of falls 
The mean vitamin D level was 33.8 ng/ml in the fractured group and 39.7 ng/ml in the control 
group (p=0.230). Distribution of patients was similar in both groups (Figure 9B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.3. Falls reported 
Patients in fractured group reported considerably more falls within one year than in the 
control group. An important finding may be that about 36.4% of fractured patients, and 30.3% 
of control patients reported more than 2 falls in the previous year (Figure 10). 
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5. DISCUSSION 
5.1. Utilisation study of anti-osteoporotic drugs 
A retrospective gender- and age-specific drug utilisation analysis was performed of 
medications indicated for the treatment of osteoporosis between 2007 and 2011 in Hungary. 
As expected, men were disproportionately undertreated in all age groups compared to women, 
and treatment choice was restricted for vitamin D, calcium supplementation and 
bisphosphonates compared to women. The persistent 10-20-fold difference between males 
and females does not reflect the estimated 1:5 proportion of males and females affected by 
osteoporosis in Hungary. In a similar age and gender-standardised Australian study, a much 
milder 3-4-fold gender difference was found between the use of alendronic- and risedronic 
acid in 2005-2006 [64]. Recently, results of numerous randomised controlled trials have 
confirmed that anti-osteoporotic drugs are equally effective in males and females [65-68]. 
Based on those findings, the recommended treatment options for male patients are calcium 
and vitamin D supplementation as first line treatment, and in combination with alendronate, 
risedronate, zoledronate, denosumab and teriparatide. All of these drugs are available in 
Hungary, however, in practice, besides health professional considerations, drug choice is also 
determined by the costs and reimbursement criteria. 
Among osteoporotic fractures, hip fractures are responsible for the greatest costs and 
high mortality rates, the male-female ratio is constant at about 30:70 [25, 28]. Based on 
international literature data, 25% of people with hip fracture die within 1 year, and the 5-year 
survival is only 41%, with an estimated 740,000 deaths worldwide [25, 69]. One year after 
hip fracture the mortality rate is almost double in men than in women: 26.8-32.5% versus 17-
21.9% [18, 23-32]. The rate of frailty and co-morbidities in men contribute to higher mortality 
rates and explains the high rate of long-term care and hospitalisation, as well as greater rates 
of smoking and alcohol abuse among men can worsen the outcome [65, 66]. Nevertheless, 
lifetime risk of osteoporotic fracture at age 50 is 20–25% in Caucasian men (versus 45–55% 
in women), which fact should not be neglected [70]. As the incidence of hip fractures showed 
an exponentially growing tendency with age in our study, adjusting the trend of anti-
osteoporotic medications to the population under the greatest risk would be considerable. 
Appropriate and proportional treatment of the 80+ populations would be an important issue in 
both men and women. Also, in case of diagnosed osteoporosis, pharmacological fracture 
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prevention may be initiated in the earliest ages as possible to reduce late-age incidence of hip 
fractures. 
A constantly growing utilisation was seen in the case of vitamin D and calcium 
compounds in both genders during the investigated period. A possible reason could be the 
increasing number of articles on vitamin D and calcium supplementation in the past 10 years 
worldwide, which resulted in wider publicity and guideline implementations of these agents 
as first-line therapy, also in Hungary.  
In contrast, bisphosphonate use showed a gradually declining tendency. The peak age of 
utilisation was 75–79 years in both genders, while in Australia the peak age was 80–89 years 
in females and 85–94 years in males [64]. This difference may be explained by the higher life 
expectancy rate at birth in Australia, which was 83 years in 2012, compared to 75 years in 
Hungary [71]. This age utilisation profile only partially corresponds to the population with the 
highest prevalence of osteoporotic fractures, as hip fractures are the highest in the 85+ 
populations in Hungary. A Swedish study also reported declining probability of 
bisphosphonate use with increasing age, especially in 85+ age groups [72]. 
Large differences were seen when comparing utilisation data of different countries. 
Unfortunately, a reliable explanation of these discrepancies or any similar comparison has not 
been found in the literature. The 2 or 3 fold differences in the utilisation rate can partially be 
explained with the different reimbursement policies of the investigated countries or difference 
in patient registration system. As an example, in Hungary, as a result of substantial cut in the 
reimbursement rate, the use of risedronic acid (monotherapy) dropped to one-third of its trade 
in 2008 compared to 2007, and it still has not reached the 2007 level in 2011.  
The different screening methods and the applied diagnostic criteria can also influence 
the use of anti-osteoporotic drugs. In Finland and in Hungary – and in most European 
countries – DEXA (Dual-Energy X-Ray Absorptiometry) is the gold standard diagnostic tool 
for osteoporosis [73]. Yet, there is a debate on the reference values of DEXA, the 
International Osteoporosis Foundation recommends a sex-specific T-score, while the WHO 
recommends using the reference values of a 20 to 30-year-old white U.S. woman to define 
DEXA T-score (-2.5 T-score) [65]. In a Dutch study, using a T-score value < -2.5, only 21% 
of men and 44% of women were identified among those sustained non-vertebral fracture [74]. 
Hence, there is a great need to develop more sensitive fracture prediction tools, and 
implement them into the diagnostic criteria. Integrating several relevant clinical risk factors, 
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FRAX is the most widely used fracture risk assessment tool for prediction of 10-year 
probability of a major osteoporotic (i.e. spine, forearm or shoulder) and hip fracture [75]. If 
available, femoral neck BMD value of the individual can be also typed in, therefore FRAX 
results can be further specified.  
Furthermore, adequate patient compliance and persistence is a crucial determinant of 
successful pharmacological therapy of osteoporosis. Compliance is defined as taking drugs as 
directed (timing, dosage and frequency) and persistence as continuing the treatment for the 
prescribed duration [76]. A novel German study found 55.2% non-compliance of more than 
10,000 treated osteoporotic patients, who were followed for one year. Compliance increased 
with age and was better in patients with previous osteoporotic fracture(s). Non-compliance 
was higher in men versus women (OR=1.15) and patients receiving oral versus injectable 
therapy (OR=1.68). Daily and monthly therapies were associated with poorer compliance than 
weekly regimens; three-or six monthly injectable therapies showed the best results [21]. 
Similarly, in a recent Italian retrospective analysis, with 30,000 osteoporotic subjects, male 
gender carried 11% higher risk of discontinuation (persistence) compared to female gender 
(HR=0.89). Also, patients who started treatment with a co-administration of calcium and 
vitamin D had a lower risk of early discontinuation (HR=0.72). The best persistence at one 
year was reported in patients treated with monthly bisphosphonates (21.6%) than subjects 
treated with daily bisphosphonates or strontium ranelate [77]. A recent Hungarian survey 
found only 24% and 39% compliance for daily and weekly oral osteoporosis therapy after 12 
months of treatment initiation, while compliance rate was 64% and 70% for 3-monthly and 6-
monthly parenteral therapy in post-menopausal women. Good compliance was associated 
with a statistically significant reduction in the risk of fracture, fracture-related hospitalisation 
and in risk of death [78]. A former British study reported that 58.3% of the patients continued 
bisphosphonate treatment for more than 1 year and 23.6% for more than 5 years. They also 
found positive correlation between weekly bisphosphonates therapy and compliance 
compared with patients using daily bisphosphonates [79]. Thus, males and patients on oral 
therapies (other than weekly regimen) should be prioritised in terms of improving compliance 
and persistence.  
Bisphosphonates are pyrophosphate analogues that bind to the hydroxyapatite crystals 
in bone tissue and suppress osteoclast-mediated bone resorption by inducing the apoptosis of 
osteoclast [80]. Advantages and efficacy of these agents in the treatment of osteoporosis are 
proven and well-established. However, growing concern has been raised regarding the 
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potential complications of prolonged bisphosphonates therapy, such as BRONJ 
(bisphosphonate-related osteonecrosis of the jaw) and atypical fractures. A systematic review 
article published wide incidence rates of BRONJ, ranging from 0.01% to 4.3% [81].  
The Hungarian Dental Association estimates 0.1-0.2% prevalence in Hungary, being higher in 
association with intravenous and anti-cancer therapy [82]. Despite BRONJ is a relatively rare 
condition, prevention and early recognition are primary, as treatment options are limited and 
the results are unsatisfying. Therefore national guidelines and literature suggest careful dental 
examination and appropriate management before the initiation of bisphosphonates therapy 
[80, 82, 83]. Atypical femoral fractures are also associated with long-term use of 
bisphosphonates, and described as ‘unusual’ low-energy fractures, with atypical radiographic 
appearance (Figure 11). They are located in the subtrochanteric region and diaphysis of the 
femur and are characterised by simple transverse, or short oblique fracture in areas of 
thickened cortices with a unicortical beaking [84-87]. The absolute risk varies between  
3.2-100 cases per 100,000 person-years, strongly depending on the duration of 
bisphosphonate therapy [84, 85, 88]. Bone healing is often delayed or failed in approximately 
30% of these patients [87, 89, 90]. Thus, in harmony with the FDA recommendations, 
interruption and evaluation of bisphosphonates therapy is suggested after 3 years of 
continuous administration. Additionally, the termination of treatment is considerable after 5 
years, as there is no evidence of further efficacy over this period of time [83, 85, 91].  
 
 
 
 
 
 
 
 
 
 
 
Figure 11 Radiographic picture of an atypical femur fracture. The arrows show the 
transversal fracture and thickened cortices with a unicortical beaking [90].  
(Permission to use images granted by Ana Méndez.) 
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The recent concerns about strontium ranelate (Protelos/Osseor) treatment must also be 
mentioned. Protelos/Osseor must not be used in patients with established, current or past 
history of ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease, 
or those with uncontrolled hypertension (European Medicines Agency letter No: 
EMA/84749/2014) [92]. These restrictions are unlikely to cause significant changes in the use 
of strontium ranelate in Hungary, as similar recommendations were in effect previously.  
5.1.1. Limitations of the study 
There are some limitations to our study. NHIF database does not provide full data 
access for research purposes, therefore the information on ICD codes and age of patients was 
not complete. Nevertheless, for our analysis ICD codes for the first 3 digits and 5-year-long 
age clusters were used. There might be some uncertainties derived from limited ICDs in the 
case of vitamin D and calcium prescriptions (E55-E58, vitamin deficiency), since the 
indication of use is widespread. However, M80 (osteoporosis with pathological fracture) and 
M81 (osteoporosis without pathological fracture) codes clearly and sufficiently refer to 
osteoporosis. Also, this database does not include over-the-counter medication claims. Thus, 
in this study we cannot estimate the OTC calcium and vitamin D consumption in Hungary.  
 
5.2. Medication use and fall prevalence among nursing home residents 
A retrospective cohort study was carried out over a period of five years (2010–2015) 
regarding the medication use and fall prevalence among nursing home residents in Szeged, 
Hungary. We found 27.9% annual fall prevalence rate among nursing home residents, which 
is slightly lower than the literature data. This fact bears evidence of the high-standard nursing 
care service the investigated nursing home provides. According to CDC and WHO reports, 
approximately 30-50% of people living in long-term care institutions fall each year, which is 
twice the rate of falls among community-dwelling older adults, and the frequency of falls 
increases with age [1, 3, 93]. Our results correspond to these findings: the age of 80 years and 
above was found to be statistically significant risk factor of falls, and fallers were 4 years 
older than non-faller residents on average. Therefore, attention should be paid to the  
80+ population, since they had almost a 4-fold risk of falling (odds ratio 3.92) compared to 
those who were under the age of 80 years.  
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Although many geriatricians consider polypharmacy (defined as taking 4 or more 
chronic medications) to be unavoidable among older patients, PP was a significant risk factor 
of falls in our study, as it is supported by different surveys and reviews [6, 13, 18].  
Higher numbers of chronic medications was a predisposing factor for falls in male 
patients. This is an important finding, since fatal fall outcome rates are much higher in men 
(46%) than in women (27%) over the age of 65 years [94]. The underlying causes of higher 
incidence in men are not obvious. Some studies found that males suffer from more co-morbid 
conditions or they may fall from greater heights and, having poorer health status, they are less 
likely to survive a fall-related injury than women of comparable age [94, 95]. Among the 
potential causes, the greater rates of smoking and alcohol abuse in men, along with commoner 
causes of secondary osteoporosis (e.g., glucocorticoid excess and hypogonadism) can be 
mentioned [65, 66]. As was highlighted earlier, the mortality rates are also nearly double in 
men than in women after sustaining a hip fracture [18, 23, 24, 29-32]. Thus guidelines and 
policies on fall prevention need to be designed on gender perspective, particularly in 
vulnerable nursing home populations.  
As the most serious non-fatal consequence of falls, bone fractures occurred in 24 
patients (43.6% among fallers). Although huge differences can be seen in fracture rates 
worldwide, our study reports higher percentages than a Sweden study (1-33%) or a US study 
(10-25%) do, and lower than the one identified in a recent Australian paper (about 48%)  
[96-98].  
One possible way of reducing fall risk (and consequences) of elderly patients is the 
frequent and regular medication review, as some of the medications are considered potentially 
inappropriate for elderly people [17, 58-60]. Although our results did not show a difference in 
the number of overall PIM-use between fallers and non-fallers, three active agents have 
emerged from the others. Neither trimetazidine nor vinpocetine have been considered as PIM 
agents in the literature previously. Pantoprazole was included in the 2015 Beers criteria, but 
was not included in any PIM lists before. The updated Beers criteria suggests the avoidance of 
the use of pantoprazole beyond 8 weeks without justiﬁcation, since long-term proton-pump 
inhibitor exposure carries high risk of Clostridium difﬁcile infection, bone loss and fractures. 
Thus, our empirical findings extend the relevancy of pantoprazole being mentioned as a PIM 
agent with a new aspect: its use showed 2.5-fold risk of falls compared to non-takers, and one 
in every six patients would be expected to experience a fall (NNH value 5.9). As stated in the 
summary of product characteristics (SPC), severe hypomagnesaemia has been reported in 
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patients, causing fatigue, tetany, delirium, convulsions and dizziness, especially on long-term 
use (more than 3 months), which can directly lead to geriatric falls [99]. As pantoprazole is an 
extensively used proton pump inhibitor, its side effects are widely studied. In fact, several 
recent articles suggest that its use in high doses over long durations (>1 year) may modestly 
increase the risk of bone fractures; thus, patients at risk of osteoporosis should receive 
adequate intake of calcium and vitamin D and should be kept under regular surveillance [99, 
100].  
Both vinpocetine (nootropic agent) and trimetazidine (anti-anginal agent) can have side 
effects that may increase the risk of falls, such as tremors, gait instability and dizziness [101-
103]. However, we could not find any research that would confirm the direct association 
between falls and the use of these medications. Our results from the binary logistic regression 
analysis revealed that taking vinpocetine will double the risk of falls (odds ratio 2.32), and the 
obtained NNH values suggest that every fourth or fifth exposure to trimetazidine or 
vinpocetine will result in a fall – within the given circumstances. We would like to emphasise 
that the role of trimetazidine as a risk factor for falls was confirmed only by univariate 
analysis. Larger patient numbers are necessary to support this finding, since the more robust 
multivariate analysis did not confirm this result. The use of tiapride (PPV (CI 95%) 0.43 
(0.27-0.60), atorvastatin 0.41 (0.27-0.58) or isosorbide mononitrate 0.45 (0.26-0.65) was 
found to be a statistically non-significant (as the confidence interval overlap the average 
annual fall rate), but still mentionable risk for falls. 
Our methods applied in this study would fit in larger population analysis as well, and it 
may allow us deeper understanding of the role of each medication (or their combinations) 
concerning falls, especially as geriatric falls are multifactorial. Hence an explicit detachment 
of the causative circumstances is challenging. Physical state, impaired balance and gait, older 
age, visual impairment, cognitive decline and environmental factors all carry remarkable fall 
risk [6, 18]. Despite these facts, the most broadly examined iatrogenic risk factors are 
polypharmacy and PIM use, since those are closely associated with ageing [9, 13-15, 17, 61]. 
As mentioned earlier, wider, comprehensive epidemiological studies would be necessary to 
confirm the role of particular active agents, and to help professionals prescribe, evaluate and 
review geriatric medication use based on real-life epidemiological data. Our results may 
contribute to and inspire further research in this field.  
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5.2.1. Limitations of the study 
The source of data for our analysis came from the same nursing home, and we did not 
have access to the medical information of deceased patients. This limitation may cause some 
bias in our results. Furthermore, while some falls may have remained hidden and unreported 
for any reason, the documented cases were well-established. Finally, larger patient data are 
needed to confirm our findings, since we had relatively small sample sizes for 
epidemiological analyses. 
 
5.3. Vitamin D levels of elderly hospitalised patients 
Serum vitamin D levels of old, hospitalised, hip fractured patients were compared to 
non-fractured hospitalised patients in a prospective pilot study. Although cholecalciferol level 
was measured during summertime, the insufficiency was markedly presented in both patient 
groups, and was higher in the fractured group. Prevalence of vitamin D deficiency was more 
than double in the fractured group. Correspondently, the mean vitamin D level was slightly 
higher in the control group. Falls were prevalent in both investigated groups: nearly 55% of 
fractured patients and roughly one-third of controls reported multiple falls in the previous 
year. However, the statistical significance could not be verified of these findings, some 
conclusions might be made. 
Many articles call our attention to the moderate or serious vitamin D hypovitaminosis, 
which affects the majority of the European, Asian and American population, mainly the 
elderly. In a Dutch study, serious 25(OH)D3 deficiency was noticed (<25 nmol/L range was 
used) in 2-30% of adults, increasing in the elderly and institutionalised to more than 80% 
across Europe [104]. According to the National Health and Nutrition Examination Survey 
(NHANES) in non-Hispanic white Americans mean serum 25(OH)D3 was about 65 nmol/L, 
but only 40 nmol/L in non-Hispanic blacks and Mexican-Americans [105]. Approximately 
10% of the inhabitants have been suffering from extreme serious hypovitaminosis D in the 
USA (<25 nmol/L) [106]. Suboptimal vitamin D levels are also common in Hungary.  
A recent study of the Semmelweis University (Budapest, Capital region of Hungary) analysed 
the results of a one-year long survey (from 2009 to 2010), which has involved nearly  
6000 patients. Suboptimal vitamin D level (<75 nmol/L) occurred in 72%, while the rate of 
serious deficiency was 12% (<35 nmol/L) [107]. Another Hungarian survey found 32% 
vitamin D insufficiency (<75 nmol/L) and 9.6% deficiency (<50 nmol/L) rates among healthy 
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blood donors in Vas County during summertime. Over 43 years, suboptimal vitamin D levels 
were more prevalent, 57% in females and 67% in males [108].  
The role of 25(OH)D3 vitamin in calcium and bone homeostasis is well-known – its 
main effects on the bone metabolism include: the increase of calcium absorption from the 
intestine, the activation of osteoblasts, differentiation of osteoclasts and the inhibition of 
parathyroid hormone synthesis [109, 110]. Adequate vitamin D status is elementary part of 
treating osteoporosis in both women and men. However, numerous studies refer to the extra-
skeletal functions of vitamin D, verifying various systemic effects of it (see Introduction 
section). The vitamin D receptor (a member of the nuclear steroid hormone receptor family) is 
almost universally expressed in nucleated cells, and the expression of several hundred known 
cytokines and molecules is being influenced by cholecalciferol [111-113]. Thus it may be 
treated as a hormone rather than a vitamin [114-117].  
Several lines of evidence support the concept that vitamin D is essential for maintaining 
muscle strength and coordination, for example the fact that genetic depletion of the receptor 
can lead to poor muscle function in mice [118]. Also, the high degree of muscle weakness in 
heritable conditions of vitamin D resistance and impaired receptor function confirms the 
strong and direct effect of vitamin D on muscles [119-121]. Vitamin D administration can 
improve the grip strength, the maximum voluntary contraction and maximal relaxation rate of 
quadriceps muscle, as well as the knee extension strength in patients with hypovitaminosis 
[122-124]. Thus, vitamin D supplementation may improve falls, as functional outcomes. In a 
meta-analysis vitamin D was associated with statistically significant reduction in the risk of 
falls (odds ratio 0.86), showing more reduction in deficient patients and when calcium was 
co-administered [40]. Vitamin D supplementation with calcium reduced the prevalence of hip 
fractures more effectively in community-dwelling elderly, than without calcium [125]. 
Vitamin D alone did not affect the mortality rate in old patients, but the risk of death was 
reduced if vitamin D was given with calcium in a Danish cohort [126].  
Nevertheless, optimal serum concentration levels of vitamin D, with respect to its extra-
osseal effects, are still debated. The British National Osteoporosis Society (NOS) suggests 
that serum 25(OH)D3 >50 nmol/L (20 ng/ml) is sufficient for almost the whole population 
[127]. The most recent Bischoff-Ferrari study set out 50-75 nmol/L (20-30 ng/ml) serum level 
as on optimal range, since higher serum vitamin D levels (over 111 nmol/L) were associated 
with more than 5 times higher risk of falls compared to the deficient group [128].   
An epidemiological study reported higher morbidity and mortality rates in patients both under 
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and over the level of 50-90 nmol/L serum vitamin D [129]. For reaching the desirable 
50nmol/L value, the Institute of Medicine recommends 600 IU (international units) daily 
vitamin D intake between the ages of 19-70, and 800 IU per day over 70 years [130].  
At the same time, under 70 years in males and under 50 years in females 1000 mg daily 
calcium intake is suggested, and 1200 mg over those ages – European recommendations 
suggest only 700-800 mg of calcium [39, 130]. The International Osteoporosis Foundation 
(IOF) and the USPSTF (U.S. Preventive Services Task Force) evaluated the fall-risk reducing 
effects of daily 800-1000 IU vitamin D intake ’convincing’ over 60 and 65 years [131, 132]. 
The Endocrine Society (ENDO) suggests general vitamin D supplementation of 800 IU over 
65 years to prevent falls [133]. The ENDO considers the optimal vitamin D level to be above 
75 nmol/L, and it can be reached by giving 1500-2000 IU daily amount, and continue as 
maintenance therapy [133]. The Hungarian guidelines (issued in 2012) agree with this 
standpoint, yet the workgroups of the consensus did not distinguish ‘elderly’ from ‘adult’ 
[116]. On the other hand, none of the health organisations recommend extreme amounts of 
vitamin D intake for extra-osseal purposes. In two studies, high dose vitamin D treatment 
(500,000 IU once yearly and 60,000 IU monthly) was associated with increased risk of falls, 
while it was not associated with better lower extremity function [128, 134].  
With respect to the origin of vitamin D, the IOF prioritises natural sources (UVB 
radiation, diet), supplemented by pharmacological vitamin D products if needed [131].  
The main vitamin D source for the majority of the population is the sunlight UVB exposure, 
rather than diet [131, 135]. Various environmental factors influence the amount of UVB 
radiation, such as latitude, weather conditions, duration of sunlight exposure, etc. [136].  
The most endangered groups under the greatest risk of vitamin D deficiency are infants and 
children under 5 years, pregnant and breastfeeding women, old people aged 65 years and 
over, people who have low or no exposure of sunlight (who are housebound or confined 
indoors for long periods, people who have darker skin, or those who cover their skin for 
cultural reason) [137]. Also, winter season is a strong determinant almost everywhere [138].  
Vitamin D treatment is essential for the populations at risk, but several precautions can 
be taken into account. In contrast with certain previous views, vitamin D supplementation in 
general populations is not recommended. Moreover, if the optimal range of vitamin D level is 
truly between 50-75 nmol/L, widespread screening of the population is essential before the 
initiation of general supplementation programme, since it is not reasonable or even riskful for 
people within the optimal range [39, 132, 133]. Several trials are in progress to clarify the role 
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and the optimal range of vitamin D under different conditions, such as cardiovascular 
diseases, cancer, diabetes or fracture [139].  
Based on the above, we can come to the conclusion that in our study, more than 50% of 
fractured patients and about one-third of controls should receive vitamin D supplementation 
and it should be between 1500-2000 IU per day until the desirable range is reached.  
If available, UVB exposure and dietary sources should be also implemented to the 
supplementation therapy. The current recommendations do not suggest higher doses than  
800 IU daily vitamin D over 70 years as maintenance dose –not even to prevent falls.  
Giving a maximum dose of 1000 mg calcium per day may also be considered.  
5.3.1. Limitations of the study 
There are some limitations to our study. Firstly, the number of patients was relatively 
small for an epidemiological study. Nonetheless, this pilot study may provide useful 
information for the health care professionals about the vitamin D status of hospitalised elderly 
patients. Secondly, lack of patient data also limited our analysis. As falls are multifactorial, 
detailed patient history (e.g. medication history, body mass indices) would have been more 
informative, as well as performing grip strength test or walking test may improve the standard 
of this study.  
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6. SUMMARY AND CONCLUSIONS 
Falls are prevalent among elderly people, leading to hospital trauma admissions and 
early death. Osteoporotic fractures, as a consequences of geriatric falls, are responsible for 
high hospital admission- and mortality rates worldwide, significantly affect quality of life, and 
put huge financial burden on the society. Undoubtedly, postmenopausal women are under the 
greatest risk of osteoporotic bone fractures; however, outcomes are even much worse among 
male patients. A retrospective gender- and age-specific drug utilisation analysis of this study 
showed that men are significantly undertreated with medications indicated for the treatment of 
osteoporosis in all age groups, compared to women. The 10 to 20-fold difference calls our 
attention to this unrecognised problem and to the need for extended screening aids. The 
incidence of hip fractures in Hungary showed an exponentially growing tendency with age in 
our study, therefore adjusting the trend of anti-osteoporotic medications to the population 
under the greatest risk (population over 80 years) would be considerable in both men and 
women. Also, based on our results, screening for osteoporosis in earlier ages, ideally  
2 or 3-yearly after menopause in women, and over 65 years in men may accurately identify 
those individuals who need medication treatment. The earlier initiation of appropriate 
osteoporosis therapy could prevent fractures in older ages and may improve mortality rates. 
Our research is the first study that provides both age- and gender-specific information on the 
use of anti-osteoporotic medications in Hungary, and according to our knowledge there is no 
such study freely available across Europe. We hope this study will be helpful not only for 
Hungarian colleagues, but also a gap-filling work for other health care professionals in 
Europe.  
Nursing home residents are especially endangered by falls, about 30-50% of people 
living in long-term care institutions fall each year, which is twice the rate of falls among 
community-dwelling older adults. Appropriate medication use is a basic factor in terms of 
falls, as some drugs may carry increased risk of falling. We performed a retrospective cohort 
study regarding medication use and fall risk among nursing home residents. Older age  
(80 years or above), polypharmacy, and the independent use of 3 active agents  
(pantoprazole, vinpocetine and trimetazidine) were found to be major risk factors for falls. 
Neither trimetazidine nor vinpocetine have been considered as PIM agents in the literature 
previously. High numbers of chronic medications taken was a significant risk factor in male 
patients. Our results showed that polypharmacy itself could be defined as an independent risk 
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factor for falls. Nevertheless, the benefit-to-risk ratio of fall-risk drugs also should be taken 
into account for safe prescribing. Drug-related problems can be reduced by means of the 
potentially inappropriate medication lists; however, these theoretical criteria need to be 
confirmed by real-life epidemiological data. Our methods and results could serve as a strong 
base for further research in this field, as well as they can attract health care professionals’ 
attention to the most vulnerable populations of elderly patients in terms of falls.  
The role of vitamin D in calcium and bone homeostasis is well-known. However, many 
research papers are dedicated and growing attention is oriented to the pleiotropic (extra-
skeletal) effects of 25(OH)D3. Vitamin D insufficiency is associated with decreased muscle- 
and grip strength, higher incidence of falls, cancer, diabetes, autoimmune- or cardiovascular 
diseases in numerous articles. In our prospective pilot study, serum vitamin D levels of 
elderly hospitalised, hip fractured patients were compared to non-fractured hospitalised 
patients. Although cholecalciferol level was measured during summertime, the insufficiency 
was markedly presented in both patient groups, and was higher (more than double) in the 
fractured group, yet we could not prove the statistical significance. Also, falls were prevalent 
in both investigated groups. Based on the current, evidence based guidelines, elderly people 
under the normal cholecalciferol level (30 ng/ml or 75 nmol/L) should receive vitamin D 
supplementation for both skeletal and extra-skeletal purposes. Nevertheless, high dose boluses 
should be avoided, because extreme amounts of vitamin D intake may increase the risk of 
falls. Sunlight exposure and dietary sources are highly recommended as part of the 
supplementation therapy.  
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Key messages and novelties 
Gender- and age-specific utilisation study of anti-osteoporotic drugs 
 Osteoporosis in no longer the condition of postmenopausal women, significant 
portion of men is also affected, and survival rate of hip fractures is worse in 
men.  
 Males over 65 years should be also screened for osteoporosis and treated 
accordingly. 
 Pharmacological fracture prevention may be started in earlier ages to reduce 
late-age incidence of hip fractures in both genders. This intervention may 
improve mortality rates and decrease fracture-related costs.  
Medication use and fall prevalence among nursing home residents 
 Geriatric falls are prevalent among individuals living in long-term care 
institutions, and are the leading causes of injury-related deaths.  
 Older age, polypharmacy, and the independent use of 3 active agents  
(pantoprazole, vinpocetine and trimetazidine) were found to be major risk 
factors for falls in our study.  
 Frequent and regular medication review is one possible way to reduce the risk of 
falling in elderly patients.  
Vitamin D levels of elderly hospitalised patients 
 Suboptimal vitamin D levels are prevalent among hospitalised older adults,  
as well as the prevalence of falls: nearly 55% of fractured patients and roughly 
one-third of controls reported multiple falls in the previous year. 
 Vitamin D insufficiency was higher among hip fractured patient compared to 
controls; however we cannot prove the statistical significance.  
 Based on current guidelines, elderly people under the normal cholecalciferol 
level (30 ng/ml or 75 nmol/L) should receive vitamin D supplementation.  
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The Hungarian PIM list 
  Drug 
ATC 
code 
Reasons Alternative drugs 
Beers    
2015  
La- 
Roche     
2007  
Priscuss      
2010  
Mann     
2011 
Risk 
of falls 
1 Liquid paraffin A06AA01 
Can lead to hypocalcaemia and 
hypokalaemia, can lead to lipid 
pneumonia in case of aspiration 
pneumonia.  
Lactulose, macrogol 
x   x x   
2 Bisacodyl A06AB02 Worsening of irritable bowel syndrome. Osmotic laxatives x x   x   
3 Sennosides A06AB06 Worsening of irritable bowel syndrome. Osmotic laxatives   x       
4 
Sodium 
picosulfate A06AB08 
Worsening of irritable bowel syndrome. Osmotic laxatives 
  x       
5 Docusate A06AG10 Worsening of irritable bowel syndrome. Osmotic laxatives   x       
6 Diphenoxylate A07DA01 
Muscarinic-blocking agents. No proven 
efficacy.  
Mebeverine, phloroglucinol 
x         
7 Glibenclamide A10BB01 
Long-acting sulphonylureas can cause an 
increased risk of hypoglycaemia.  
Short-acting sulphonylureas 
      x   
8 Ticlopidine B01AC05 
Can lead to life-threatening 
haematological side effects, including 
neutropenia/agranulocytosis, thrombotic 
thrombocytopenic purpura, and aplastic 
anaemia, may cause altered blood counts.  
Clopidogrel, acetylsalicylic-acid 
x x x x   
9 Prasugrel B01AC22 
May cause altered blood counts. 
Unfavorable risk/benefit ratio, 
particularly over 75 years.  
Clopidogrel, acetylsalicylic-acid 
    x     
10 Ferrous sulfate B03AA02     x         
11 Digoxin C01AA05 
Increased sensitivity of the elderly. The 
dose should remain ≤0.125 mg/day or 
preferably should be adapted to maintain 
serum concentration < 1.2 ng/ml. Risk of 
overdose in renal insufficiency: nausea, 
vomiting, drowsiness, visual 
disturbances, cardiac rhythm 
disturbances.  
Digoxin dose ≤0.125 mg/day or 
serum concentration between  
0.5 and 1.2 ng/ml.  
x x x x YES 
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12 Quinidine C01BA01 
Central nervous side effects, increased 
mortality. Quinidine plus verapamil: not 
recommended for patients over age 75.  
Monitoring for central nervous effects, 
monitoring of cardiovascular function 
(proarrhythmia, QT duration), monitoring 
of renal function. 
Beta-blockers, verapamil, diltiazem, 
amiodarone, defibrillator 
implantation.  
    x     
13 Disopyramide C01BA03 Heart failure, anticholinergic effect.  Amiodarone, other antiarrhythmics x x     YES 
14 Propafenone C01BC03 
Pro-arrhythmogenic effect can lead to 
AV block, intraventricular conduction 
delays, common neurotoxic and 
gastrointestinal side effects.  
Indication of cardioversion: 
amiodarone, indication of frequency 
control: beta-blockers, verapamil, 
diltiazem, digitoxin.  
      x   
15 Flecainide C01BC04 
Higher rate of adverse effects in general, 
pro-arrhythmogenic effect can lead to 
ventricular arrhythmias, ventricular 
fibrillation and cardiac arrest.  
Beta-blockers, amiodarone, 
verapamil, diltiazem, digitoxin. 
Monitoring for central nervous 
effects (e.g., vertigo, cognitive 
impairment), monitoring of 
cardiovascular function, monitoring 
of renal function (dose adjustment).  
    x x YES 
16 Amiodarone C01BD01 
Common side effects: extra-pyramidal 
tremors, insomnia, nightmares. Inhibition 
of liver enzimes.  
  
x       YES 
17 Dronedarone C01BD07 
Severe liver dysfunction up to liver 
failure, increased mortality in patients 
with heart failure, “reserve drug” for 
amiodarone or beta-blockers in KI, 
indication made by specialists.  
Indication of cardioversion: 
amiodarone, indication of frequency 
control: beta-blockers.        x   
18 Methyldopa C02AB01 
Can cause orthostatic hypotension, can 
cause sedation.  
  
x x   x YES 
19 Guanfacine C02AC02 
The aged are more sensitive to sedation, 
hypotension, bradycardia, syncope.  
Other antihypertensive drugs, except 
short-acting calcium-channel 
blockers and reserpine. 
  x     YES 
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20 Moxonidine C02AC05 
The aged are more sensitive to sedation, 
hypotension, bradycardia, syncope.  
Other antihypertensive drugs, except 
short-acting calcium-channel 
blockers and reserpine. 
  x     YES 
21 Rilmenidine C02AC06 
The aged are more sensitive to sedation, 
hypotension, bradycardia, syncope.  
Other antihypertensive drugs, except 
short-acting calcium-channel 
blockers and reserpine. 
  x     YES 
22 Prazosine C02CA01 
Aggravation of urinary incontinence, 
postural hypotension. 
Monitoring of cardiovascular 
function 
  x x   YES 
23 Doxazosin C02CA04 
Hypotension (positional), dry mouth, 
urinary incontinence/impaired 
micturition. 
Monitoring of cardiovascular 
function x   x   YES 
24 Urapidil C02CA06 
Aggravation of urinary incontinence, 
postural hypotension.  
Monitoring of cardiovascular 
function 
  x     YES 
25 Ethacrynic acid C03CC01 Can cause postural hypotension.    x       YES 
26 Pentoxifylline C04AD03 Hypotension   x x x x YES 
27 Nicergoline C04AE02 
No really proven efficacy while postural 
hypotension and fall risks are increased 
with most vasodilators.  
  
  x x x YES 
28 Naftidrofuryl C04AX21 
No really proven efficacy while postural 
hypotension and fall risks are increased 
with most vasodilators.  
  
  x x x YES 
29 Sotalol C07AA07 
Pro-arrhythmogenic effect, can lead to 
torsade de pointes or ventricular 
tachycardia/ventricular fibrillation, QT 
interval prolongation, and accumulation 
in patients with renal insufficiency.  
Other beta-blockers (except atenolol, 
which has unfavourable data 
regarding the endpoint of stroke).      x x   
30 Nifedipine C08CA05 
Postural hypotension, myocardial 
infarction or stroke.  
Other antihypertensive drugs, except 
centrally acting antihypertensives 
and reserpine.  
x x x x YES 
31 Oxybutynin G04BD04 
Can cause delirium and cognitive 
impairment, can worsen glaucoma and 
lead to partial or complete 
gastrointestinal obstruction.  
Trospium chloride 
x x x x YES 
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32 Tolterodine G04BD07 
Can cause delirium and cognitive 
impairment, can worsen glaucoma and 
lead to partial or complete 
gastrointestinal obstruction.  
Trospium chloride 
  x x x YES 
33 Solifenacin G04BD08 
Anticholinergic side effects (e.g., 
constipation, dry mouth, CNS ), ECG 
changes (prolonged QT).  
  
  x x   YES 
34 Terazosine G04CA03 
Increased risk of cerebrovascular and 
cardiovascular disease.  
  
    x     
35 Nitrofurantoin J01XE01 
Unfavorable risk/benefit ratio, 
particularly with long-term use 
(pulmonary side effects, liver damage, 
etc.)  
Other antibiotics (e.g., 
cephalosporins, cotrimoxazole, 
trimethoprim—in accordance with 
sensitivity and resistance testing, as 
far as possible). Non-
pharmacological measures: more 
fluid intake, incontinence aids. 
Monitoring of renal, pulmonary, and 
hepatic function.  
x x x     
36 Celecoxib L01XX33 
Serious adverse drug reactions: 
gastrointestinal ulcers, bleeding, kidney 
and liver insufficiency, hypertension.  
  
      x   
37 Indomethacin M01AB01 
Highest incidence of CNS side effects 
(e.g. delirium) of all NSAIDs. Very high 
risk of gastrointestinal haemorrhage.  
Paracetamol or other NSAID.  
x x x x   
38 Diclofenac M01AB05 
Serious adverse drug reactions: 
gastrointestinal ulcers, bleeding, kidney 
and liver insufficiency, hypertension.  
In the analgetic indication: 
paracetamol, metamizole, 
hydromorphone.  
      x   
39 Ibuprofen M01AE01 
Serious adverse drug reactions: 
gastrointestinal ulcers, bleeding, kidney 
and liver insufficiency, hypertension.  
  
      x   
40 Acemetacin M01AB11 
Serious adverse drug reactions: 
gastrointestinal ulcers, bleeding, kidney 
and liver insufficiency, hypertension.  
In the analgetic indication: 
paracetamol, metamizole, 
hydromorphone. 
    x x   
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41 Piroxicam M01AC01 
Serious adverse drug reactions: 
gastrointestinal ulcers, bleeding, kidney 
and liver insufficiency, hypertension.  
In the analgetic indication: 
paracetamol, metamizole, 
hydromorphone. 
x   x x   
42 Meloxicam M01AC06 
Serious adverse drug reactions: 
gastrointestinal ulcers, bleeding, kidney 
and liver insufficiency, hypertension.  
In the analgetic indication: 
paracetamol, metamizole, 
hydromorphone. 
    x x   
43 Naproxen M01AE02 
Serious adverse drug reactions: 
gastrointestinal ulcers, bleeding, kidney 
and liver insufficiency, hypertension.  
In the analgetic indication: 
paracetamol, metamizole, 
hydromorphone. 
x     x   
44 Ketoprofen M01AE03 
Serious adverse drug reactions: 
gastrointestinal ulcers, bleeding, kidney 
and liver insufficiency, hypertension.  
In the analgetic indication: 
paracetamol, metamizole, 
hydromorphone. 
    x x   
45 
Mefenamic 
acid M01AG01 
Serious adverse drug reactions: 
gastrointestinal ulcers, bleeding, kidney 
and liver insufficiency, hypertension.  
In the analgetic indication: 
paracetamol, metamizole, 
hydromorphone. 
x         
46 Etoricoxib M01AH05 
Cardiovascular contraindications.  In the analgetic indication: 
paracetamol, metamizole, 
hydromorphone. 
    x     
47 Chlorzoxazone M03BB03     x       YES 
48 Baclofen M03BX01 
Common side effects: delirium, falls, 
headache, sedation, drowsiness, amnesia.  
Thiocolchicoside, mephenesine 
  x x x YES 
49 Pethidine N02AB02 
The major metabolite normeperidine can 
cause convulsions, delirium, sedation, 
and respiratory depression.  
Hydromorphone 
    x x YES 
50 Buprenorphine N02AE01 
CNS side effects: sedation and delirium, 
gastrointestinal effects: nausea at the 
beginning and constipation with medium- 
and long-term administration, 
anticholinergic side effects.  
Hydromorphone 
      x YES 
51 Tramadol N02AX02 
Lowers seizure threshold, may lead to 
delirium. Frequent unwanted side effects: 
vomiting, vertigo, constipation.  
Paracetamol, metamizole, 
hydromorphone.        x YES 
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52 
Acetylsalicylic 
acid N02BA01 
High rate of gastrointestinal side effects 
(bleeding) in/with long-term use.  
In the analgetic indication: 
paracetamol, metamizole, 
hydromorphone.  
      x   
53 Ergotamine N02CA52 
Vasoconstriction can lead to angina 
pectoris, hypertension, glaucoma, liver 
and renal impairment, urinary retention 
and cramping. Unfavorable risk/benefit 
profile.  
Therapy waiver 
    x     
54 Phenobarbital N03AA02 
Sedation, paradoxical excitation, clinical 
monitoring for adverse effects (testing of 
gait steadiness, coordination; 
psychopathology).  
Other antiepeleptic drugs: 
lamotrigine, valproic acid, 
levetiracetam, gabapentin.  
    x x YES 
55 Phenytoin N03AB02 
CNS depression, including delirium, 
tremor, ataxia, nystagmus, anaemia and 
osteomalacia.  
  
      x YES 
56 Clonazepam N03AE01 
CNS depression, including delirium, 
depression, amnesia and ataxia.  
  
      x YES 
57 Biperiden N04AA02 
Anticholinergic side effects: restlessness, 
delirium, urinary retention and negative 
effect on cognitive functions.  
L-dopa 
  x   x YES 
58 Ropinirole N04BC04 
Higher potential for hallucinations and 
delirium.  
  
      x   
59 Pramipexole N04BC05 
Higher potential for hallucinations and 
delirium.  
  
      x   
60 Rotigotine N04BC09 
Higher potential for hallucinations and 
delirium. 
  
      x   
61 
Levome-
promazine N05AA02 
Main side effects: anticholinergic 
(urinary retention, constipation, visual 
disturbances), cognitive impairment, 
noradrenergic (orthostatic hypotension), 
antihistaminergic (sedation), 
extrapyramidal symptoms including 
Parkinson-like symptoms, dystonia, 
akathisia and tardive dyskinesia.  
So-called atypical neuroleptics.  
  x x x YES 
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62 Fluphenazine N05AB02 
Main side effects: anticholinergic 
(urinary retention, constipation, visual 
disturbances), cognitive impairment, 
noradrenergic (orthostatic hypotension), 
antihistaminergic (sedation), 
extrapyramidal symptoms including 
Parkinson-like symptoms, dystonia, 
akathisia and tardive dyskinesia.  
So-called atypical neuroleptics.  
  x x x YES 
63 Pipotiazine N05AC04 
Muscarinic-blocking drugs. Second 
choice drugs.  
Atypical antipsychotics with less 
anticholinergic activity (clozapine, 
risperidone, olanzapine, amisulpride, 
quetiapine), meprobamate.  
  x       
64 Haloperidol N05AD01 
Main side effects: anticholinergic 
(urinary retention, constipation, visual 
disturbances), cognitive impairment, 
noradrenergic (orthostatic hypotension), 
antihistaminergic (sedation), 
extrapyramidal symptoms including 
Parkinson-like symptoms, dystonia, 
akathisia and tardive dyskinesia. 
So-called atypical neuroleptics.  
    x x YES 
65 Clozapine N05AH02 Can cause agranulocytosis.       x x   
66 Olanzapine N05AH03 
Extrapyramidal and anticholinergic side 
effects, sedation, and cognitive 
impairment especially with higher doses. 
  
    x x YES 
67 Diazepam N05BA01 Prolonged reaction times.  Opipramol x x x x YES 
68 
Chlor-
diazepoxide N05BA02 
Risk of falling (muscle-relaxing effect) 
with risk of hip fracture.  
Short-(/shorter-)acting 
benzodiazepines, zolpidem, 
zopiclone, zaleplone at a low dose.  
x x x x YES 
69 Medazepam N05BA03 Long-acting benzodiazepines       x   YES 
70 Clobazam N05BA09 
Long-acting benzodiazepines, protracted 
activity, increased likelihood of adverse 
effects occurrence (drowsiness, falls).  
  
  x x   YES 
71 Alprazolam N05BA12 Long-acting benzodiazepines   x x x   YES 
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72 Meprobamate N05BC01 Long-acting benzodiazepines   x x     YES 
73 Nitrazepam N05CD02 
Long-acting benzodiazepines, protracted 
activity, increased likelihood of adverse 
effects occurrence (drowsiness, fall).  
  
  x x x YES 
74 Temazepam N05CD07 Long-acting benzodiazepines   x x x     
75 Brotizolam N05CD09 
Short- and intermediate acting 
benzodiazepines (>0.125 mg/day).    
    x x   
76 Zopiclone N05CF01 Delayed reaction time (>3.75 mg/day).      x x   YES 
77 Zolpidem N05CF02 
Risk of falling and hip fracture  
(>5 mg/d). 
Combining form: short- and 
intermediate-acting benzodiazepines.    x x   YES 
78 Zaleplone N05CF03 
Psychiatric reactions (sometimes 
paradoxical, e.g., agitation, irritability, 
hallucinations, psychosis), cognitive 
impairment (>5 mg/d).  
  
    x   YES 
79 Imipramine N06AA02 
Drowsiness, inner unrest, confusion, 
muscarinic-blocking agents with 
cardiotoxicity when overdosed. 
Non-pharmacological treatments 
such as behavioral therapy. x x x   YES 
80 Clomipramine N06AA04 
Muscarinic-blocking agents with 
cardiotoxicity when overdosed. 
  
  x x x YES 
81 Trimipramine N06AA06 
Muscarinic-blocking agents with 
cardiotoxicity when overdosed. 
  
  x x   YES 
82 Amitriptyline N06AA09 
Muscarinic-blocking agents with 
cardiotoxicity when overdosed. 
  
x x x x YES 
83 Maprotiline N06AA21 
Muscarinic-blocking agents with 
cardiotoxicity when overdosed. 
  
  x x x YES 
84 Fluoxetine N06AB03 
Common side effects: headache, 
insomnia, drowsiness, ataxia, tremor, 
convulsions.  
  
x   x   YES 
85 Fluvoxamine N06AB08 
Nausea, vomiting, drowsiness, dizziness, 
dry mouth, constipation, diarrhoea, 
weight loss/anorexia.  
Other SSRIs; SNRIs; mirtazapine. 
      x YES 
86 Piracetam N06BX03 
Increased risk of orthostatic hypotension 
and falls and/or efficacy not proven.  
Therapy waiver 
  x x x YES 
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87 Ginkgo Biloba N06DX02 
No proven efficacy, high risk of postural 
hypotension and falls.  
  
  x   x YES 
88 Hydroxyzine N07XX04 
Can cause delirium and anticholinergic 
side effects like dry mouth, urinary 
retention, and constipation, and can cause 
QT interval prolongation.  
  
x x x x YES 
89 Theophylline R03DA04 
Can cause atrial fibrillation and atrial 
flutter and tachycardia, cardiac 
arrhythmia, seizures, insomnia and 
irritability, vomiting and diarrhoea; dose-
dependent.  
Inhalational drugs including 
tiotropium, glucocorticoids and long-
acting beta-sympathomimetic drugs.        x   
90 
Diphen-
hydramine R06AA02 
Anticholinergic effects, dizziness, ECG 
changes.  
Monitor for anticholinergic side 
effects, ECG.  x x x   YES 
91 Dimetindene R06AB03 ECG changes (prolonged QT).        x     
92 Promethazine R06AD02 
Other drugs with anticholinergic 
properties. No proven efficacy. 
Muscarinic-blocking agents, can cause 
confusion, sedation. 
Nausea: domperidone. Cough: 
clobutinol, olexadine. Drowsiness: 
acetyl-leucine, betahistine. Rhinitis: 
saline.  
x x       
93 
Cypro-
heptadine R06AX02 
Muscarinic-blocking drugs, can cause 
sedation, drowsiness. 
Cetirizine, desloratadine, loratadine. 
x x       
94 Clonidine S01EA04 
The aged are more sensitive to sedation, 
hypotension, bradycardia, syncope.  
Other antihypertensive drugs, except 
short-acting calcium-channel 
blockers and reserpine.  
x x   x YES 
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